With all the fancy predictive analytics that firms have adopted in recent years, why are they still slow to respond once they know a disruption is coming down the line?
GLP-1 drugs are forcing companies to adapt to a sustained shift in consumer behavior and healthcare demand that touches both food and pharma supply chains.
In the lead-up to July's joint review of the USMCA, companies are left to wonder if a full withdrawal from the deal is actually on the table for the U.S.